FA
EVH icon

Friess Associates’s Evolent Health EVH Stock Holding History

Friess Associates’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-137,450
Closed -$2.74M – 130
2018
Q4 		$2.74M Buy
+137,450
New +$3.18M 0.23% 91
2017
Q3 		– Sell
-393,163
Closed -$9.97M – 107
2017
Q2 		$9.97M Buy
393,163
+183,163
+87% +$4.41M 0.91% 60
2017
Q1 		$4.68M Buy
210,000
+182,500
+664% +$3.5M 0.44% 73
2016
Q4 		$407K Sell
27,500
-272,500
-91% -$5.37M 0.04% 105
2016
Q3 		$7.39M Buy
+300,000
New +$7.01M 0.72% 64

Other funds holding EVH

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Friess Associates's EVH Position: Q1 2019 in Review

Friess Associates sold out of Evolent Health (EVH) in Q1 2019, closing a stake of 137,450 shares — an estimated $2.74M sold.

Friess Associates first reported a position in EVH in Q3 2016 and held it in 5 quarters. The position peaked at $9.97M in Q2 2017. 192 funds tracked by Wall St. Rank hold EVH as of Q1 2019.

  • Friess Associates reported no remaining Evolent Health position as of Q1 2019 after selling out during the quarter.
  • Friess Associates sold 137,450 Evolent Health shares in Q1 2019, an estimated $2.74M.
  • Friess Associates first reported a position in Evolent Health in Q3 2016 and held it in 5 quarters.
  • Friess Associates's Evolent Health position peaked at $9.97M in Q2 2017.
  • 192 funds tracked by Wall St. Rank held Evolent Health as of Q1 2019.

Based on Friess Associates's 13F filing for Q1 2019, filed 15 May 2019.